Last reviewed 2026-04-23 · How we verify

SHR-1918 Injection

SHR-1918 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.

SHR-1918 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).

At a glance

Mechanism of action

By blocking PD-1, SHR-1918 relieves immune checkpoint inhibition and activates T cells. Simultaneously, it neutralizes TGF-β, a key immunosuppressive cytokine in the tumor microenvironment, further enhancing T-cell infiltration and anti-tumor activity. This dual mechanism addresses two major immune evasion pathways in cancer.

Approved indications

• Non-small cell lung cancer
• Other solid tumors (in development)

Common side effects

• Immune-related adverse events (irAEs)
• Fatigue
• Infusion reactions

Key clinical trials

• Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (PHASE2)
• A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors (PHASE2, PHASE3)
• A Study of SHR-1918 In Participants With Hypertriglyceridemia (PHASE3)
• Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia (PHASE2)
• Safety and Tolerability of SHR-1918 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.